× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Findings

What does this study add?

  • Pain freedom was achieved in 44% of migraine headaches and freedom from MBS in 62%.
  • Results were similar to those reported in the ZOTRIP trial: both trials exceeded 40% in pain freedom at 2 hours.
  • At 2–24 hours both trials’ sustained pain freedom rates exceeded 30%.
  • The pattern of adverse events (AEs) was similar to the ZOTRIP trial; nearly all mild and the most common were redness and swelling at the application site.